Breast Cancer — SABCS*
Mixed results for targeted agents in breast cancer
Expires: December 13, 2010
This activity reviews the results of several studies presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS) that assessed targeted therapy plus chemotherapy in patients with advanced breast cancer; these studies yielded mixed results. Upon reading the article, participants must correctly answer two multiple-choice questions to receive credit.
Benefits of bevacizumab modest in metastatic disease Credits: 0.25 Fee: None Expires: December 15, 2010
This activity reviews two studies presented at SABCS that showed only a limited increase in survival when bevacizumab was added to a chemotherapy regimen for patients with metastatic breast cancer. Upon reading the article, participants must correctly answer two multiple-choice questions to receive credit.
http://tinyurl.com/y9rtcpb HER2 combo boosts metastatic breast cancer survival
Expires: December 15, 2010
This activity is based on a study presented at SABCS that shows that a dual biologic attack on heavily pretreated metastatic breast cancer with lapatinib and trastuzumab may substantially prolong survival, without chemotherapy or endocrine therapy. Upon reading the article, participants must correctly answer two multiple-choice questions to receive credit.
www.medpagetoday.com/MeetingCoverage/ SABCS/17536 Vitamin D reduces aromatase inhibitor pain Credits: 0.25 Fee: None
December 15, 2010
This activity is based on a study presented at the 2009 American Society of Hematology (ASH) annual meeting that indicated that a highdose of vitamin D might relieve musculoskeletal pain caused by treatment of breast cancer with aromatase inhibitors. Upon reading the article, participants must correctly answer two multiple-choice questions to receive credit.
*More SABCS CME opportunities are available at medpage Today at www.medpagetoday.com/ MeetingCoverage/SABCS.
Expires: Colorectal Cancer —
Surgical approach to liver-limited metastatic colorectal cancer
Expires: September 15, 2010
Participants are required to read an E-Update in which experts write about recent liver-limited colon cancer advances. The update discusses biologic, surgical, and toxicity issues in liver-limited disease. Successful completion of a posttest with a passing score of 80% or better earns the participant the credits. The activity in its entirety should take approximately 2 hours to complete. http://tinyurl.com/yae5rj6
Kidney Cancer —
Management of small renal masses: What is the best management option in this case?
Expiration: January 21, 2010
Multimedia: Webcast At the conclusion of this activity, participant will be able to contrast the benefits and pitfalls of specific management options for patients that present with an incidental renal mass, including radical nephrectomy, partial nephrectomy, energy ablation, and active surveillance; discuss the potential morbidity associated with active surveillance strategies, including the risk of local and metastatic progression; and explain issues of patient selection for appropriate management for a small renal mass.
Innovations and challenges in renal cancer
Expiration: May 2010
Following completion of this activity, participants should be able to discuss how recognized molecular targets in renal cancer are related to prognosis and current and future therapeutic approaches; discuss current approaches to prognostic classification in renal cancer as they relate to treatment selection and expectation; and assess recent clinical data for immunotherapies and targeted and anti-angiogenic therapies in renal cancer treatment. http://tinyurl.com/y8co2u5
Lung Cancer —
Management of stage III, N2 NSCLC: A virtual thoracic oncology tumor board
Expires: June 30, 2010
This Webcast-based activity features a team of multidisciplinary medical experts in a virtual tumor reviewing the case of a 55-year-old man with stage III, N2 non—small cell lung cancer (NSCLC). The goal of this activity is to demonstrate the many different options available for staging and treating such cases by examining current and emerging strategies in the management of patients with lung cancer. After completing this activity, participants will understand how to assess, diagnose, and stage lung cancer using the newest staging systems, tumor node metastases classification, tumor location, performance status, and surgical respectability to determine the stage-specific treatment methods. Participants will also be able to describe the appropriate use of chemotherapeutic agents and radiation therapies in treatment strategies for lung cancer patients that improve outcomes through knowledge of their efficacy and safety, and integrate targeted therapies into more successful treatment regimens for patients with lung cancer by evaluating the safety and efficacy of these agents.
Treatment paradigms in advanced non-small cell lung cancer: The evolving role of maintenance therapy
Expires: September 1, 2010
This activity focuses on different treatments and therapies used to manage various stages of lung cancer. Upon completing this activity, participants should be able to use MAbs and EGFR/TK inhibitors in the front-line treatment of lung cancer. They should also have a better understanding of how to effectively use maintenance chemotherapy in the treatment of lung cancer. http://tinyurl.com/ylxb3ea
Review of evidence-based support for pretreatment imaging in melanoma
Expiration: April 15, 2010
Upon completion of this activity, participants will be able to identify prognostic factors in patients with newly diagnosed melanoma; define the recommendations for pretreatment imaging from the National Comprehensive Cancer Network in patients with melanoma; describe the types of pretreatment imaging techniques used in patients with melanoma; describe imaging techniques for identifying regional lymph node metastases in patients with newly diagnosed melanoma; and describe biochemical tests used for assessing prognosis in patients with melanoma.
A reappraisal of the significance of largest basal diameter of posterior uveal melanoma
Expiration: April 15, 2010
Upon completion of this activity, participants will be able to describe the features of uveal melanoma likely to be predicted by largest tumor diameter, identify the most common treatment strategies for uveal melanoma, describe mortality associated with chromosome deletions and gains in patients with uveal melanoma, and describe the histologic and demographic factors associated with metastatic death from uveal melanoma, describe the predictive value of largest tumor diameter for disease-specific mortality in patients with uveal melanoma.
Saliva test for microRNA could detect oral cancer
Expiration date: August 25, 2010
This activity involves reading a short news story discussing a study that examined miRNAs in saliva as oral cancer biomarkers and answering two multiple-choice questions. Upon completing the activity, participants should be able to discuss the results of this study and review its relevance and significance in the broader context of clinical care.
Fatty diet linked to pancreatic Cancer
Expires: June 26, 2010
This activity requires reading a short news story and answering two multiple-choice questions on an article published in the Journal of the National Cancer Institute that found that diets high in fat, especially fat from meat and dairy products, were linked to an increased risk of pancreatic cancer. Upon completing this educational program, participants should be able to discuss the results of this study with their patients and review the relevance and significance of the study in the broader context of clinical care.
Improving outcomes in pancreatic cancer: Existing options and novel approaches
Expires: July 15, 2010
Upon completing this educational activity, participants should be able to discuss the diagnostics involved in the staging process for pancreatic cancer and how this knowledge provides opportunity to more accurately diagnose pancreatic cancer in early stages; incorporate national clinical guidelines regarding surgical resection and adjuvant therapy into management plans that address preoperative, intraoperative, and postoperative concerns; and discuss clinical trial data results from new combinations of existing treatments and novel targeted therapies for pancreatic cancer.
New treatment paradigms in pancreatic cancer
Expires: November 15, 2010
Upon completing this activity, participants should be able to apply an adjuvant treatment framework based on scientific studies, analyze the role of radiation therapy in locally advanced pancreatic cancer, demonstrate an understanding of the current treatment options for metastatic pancreatic cancer, appraise novel treatments currently being studied, and deliver optimal palliative care to patients with advanced pancreatic cancer.
Clodronate improves survival in metastatic prostate cancer
Expires: August 11, 2010
Upon completing this activity, participants should be able to explain to patients that treatment with sodium clodronate improved overall survival in men with metastatic prostate cancer to bone. This finding is based on the results of a trial published in the August 11 issue of The Lancet Oncology. Upon reading the article, participants must correctly answer two multiple-choice questions to receive credit.
Radiation-induced hypopituitarism after cancer therapy: Who, how, and when to test Credits: 1
Expires: January 23, 2010
Upon completing this activity, participants should be able to describe the types of tumors at risk for irradiation-induced hypopituitarism, recognize factors affecting the severity and onset of radiation-induced hypopituitarism, identify the hormonal axis most susceptible to radiation-induced hypothalamic-pituitary axis (HPA) damage, list the types of endocrine dysfunctions associated with radiation-induced HPA damage, and describe treatment strategies for endocrine abnormalities associated with radiation-induced HPA damage.
href="file:///C:%5CUsers%5Cdcoffey%5CAppData%5CLocal%5CTemp%5Cmsohtmlclip1%5C01%5Cclip_filelist.xml" rel="File-List" />